Keystone Nano begins Phase I of Ceramide NanoLiposome

In April, Keystone Nano Inc. (State College, Pa.) began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV Ceramide NanoLiposome in about 24 patients with advanced solid tumors. The primary endpoint of the trial will identify a maximum tolerated dose (MTD). Secondary endpoints include a recommended Phase II dose, safety, pharmacokinetics and objective response rate (ORR). The company said a Phase II trial is expected to focus on liver cancer...